|
WO2004091621A1
|
|
Alternating treatment of cancer with topoisomerase i and topoisomerase ii inhibitors
|
|
US2003212087A1
|
|
Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
|
|
US6699875B2
|
|
Cascade esters of camptothecins and methods of treating cancer using these compounds
|
|
US6407118B1
|
|
Derivatives of camptothecin and methods of treating cancer using these derivatives
|
|
USRE38408E
|
|
Methods of preparing and purifying 9-nitro-20-camptothecin
|
|
US6352996B1
|
|
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
|
US6096336A
|
|
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
|
US6228855B1
|
|
Aromatic esters of camptothecins and methods to treat cancers
|
|
US5922877A
|
|
Methods of preparing and purifying 9-nitro-20-camptothecin
|
|
US6080751A
|
|
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
|
US5731316A
|
|
Derivatives of camptothecin and methods of treating cancer using these derivatives
|
|
US5552154A
|
|
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
|
US5527913A
|
|
Methods for purifying camptothecin compounds
|
|
EP0678025A1
|
|
Transdermal treatment of cancer with water-insoluble s-camptothecin of the closed lactone ring form
|
|
US5352789A
|
|
Methods for purifying camptothecin compounds
|
|
CA2087209A1
|
|
Method for treating malignant tumors with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
